title: [Adjuvant chemotherapy with UFT or UFT with OK-432 to patients with gastric and colorectal cancer. Kanto Adjuvant Study Group].
abstract: In Japan, long-term oral therapy with tegafur in combination with immunopotentiators is commonly used as adjuvant therapy after curative resection of gastric or colorectal can for gastric and colorectal cancer. When the outcome was analyzed in terms of the relative performance (R.P.) and the individual dose intensity (I.D.I.) of OK-432, gastric cancer patients with a R.P. of 0.5 or higher tended to have a better survival curve. There were no marked differences in lymphocytes subsets, except that the Leu 7 level at 3 months after gastric cancer resection was significantly higher (p < 0.05) in group B than in group A. Thus, no inhibition of the anticancer effect of UFT was noted during long term combination therapy with UFT and an immunopotentiator as postoperative adjuvant therapy for patients who underwent curative resection of gastric or colorectal cancer. The results suggest that UFT combined with long-term OK-432 maintenance therapy may contribute to improve survival rates in gastric cancer patients.
authors.forename: T
authors.initials: T
authors.lastname: Konishi
authors.forename: Y
authors.initials: Y
authors.lastname: Idezuki
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Haga
authors.forename: Y
authors.initials: Y
authors.lastname: Ushirokouji
authors.forename: K
authors.initials: K
authors.lastname: Shinohara
authors.forename: M
authors.initials: M
authors.lastname: Shibusawa
authors.forename: Y
authors.initials: Y
authors.lastname: Bandai
authors.forename: M
authors.initials: M
authors.lastname: Hiraishi
authors.forename: N
authors.initials: N
authors.lastname: Murata
authors.forename: K
authors.initials: K
authors.lastname: Yabe
authors.forename: T
authors.initials: T
authors.lastname: Yamamura
authors.forename: S
authors.initials: S
authors.lastname: Yumoto
authors.forename: A
authors.initials: A
authors.lastname: Gunji
authors.forename: M
authors.initials: M
authors.lastname: Nishigaki
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D018572:Disease-Free Survival; D004338:Drug Combinations; D006801:Humans; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage*; D012004:Rectal Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D013274:Stomach Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D010844:Picibanil; D014498:Uracil